AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00930930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00930930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally
Study NCT00930930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV
Study NCT00930930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00930930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00930930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venous blood draw
Description: Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
Study NCT00930930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venous blood draw
Description: Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
Study NCT04308629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Study NCT04308629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Study NCT03053843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus extra virgin olive oil
Description: The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet
Study NCT05641636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis
Description: Echocardiography - standart protocol. Pulse wave characteristics were obtained using finger photopletysmography (PPG) (Angioscan-01, AngioScan-Electronics) from an infrared light sensor. Endothelial function was also evaluated using occlusion index and shear rate during post-occlusive reactive hyperemia (PORH). CPET was conducted on a treadmill (Intertrack 8100, Schiller, Switzerland) with a breath-by-breath algorithm of gas exchange analysis (Cardiovit CS-200 Ergo-Spiro, Schiller, Switzerland), using Bruce, modified Bruce or Naughton protocols depending on the level of physical tolerance.
Study NCT05830175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy for cervikal region
Description: Joint mobilization: In the stroke individuals included in the mobilization group, Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization was applied with the Maitland method starting from the upper cervical region towards the lower cervical region, in 3 sets, 2 minutes and 1 minute rest.
Study NCT05830175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic suboccipital myofascial release technique
Description: The patient lies comfortably in the supine position. The therapist's forearms are supported on the treatment table, with the metacarpophalangeal and proximal interphalangeal joints flexed to approximately 45 degrees. After the therapist places his hands on the area where the patient's suboccipital muscles connect the occiput, he asks the patient to relax and rest his head on his fingers. Therapist pays attention to positioning the fingertips in suboccipital area No traction is performed during this technique. The position is maintained until the patient is relaxed. This treatment takes approximately 3-4 minutes.
Study NCT00623870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: Multiple ascending doses
Study NCT01814124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy plus exercise
Study NCT01814124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advice and home exercise
Study NCT01814124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advice and home exercise
Study NCT02431208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.
Study NCT02431208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Participants will receive either 20mg or 40mg of dexamethasone PO every 7 days from Day 1 of each cycle.
Study NCT01541930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK567
Description: Once or twice daily, for 14 days, up to 30 g per day
Study NCT02484703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
Study NCT02484703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5186582
Description: Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
Study NCT03416400 — intervention group
Intervention type: OTHER
Intervention: Oocyte vitrification
Description: Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from patient diagnosed with cancer will be included in this study. Oocytes were matured in vitro with IVM medium and vitrified in closed system (Vitrolife). Kinetic of maturation were analyzed by Primovision (Vitrolife) and actin, and spindle organization were studied by microscopy, immunostaining techniques and quantitive analysis.
Study NCT00098111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine
Study NCT03759067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel 75mg
Description: clopidogrel once daily 75mg
Study NCT03759067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel 75mg
Description: clopidogrel once daily 75mg
Study NCT03759067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 300 mg
Description: clopidogrel 300mg reloading
Study NCT03759067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel 600mg
Description: clopidogrel 600mg loading
Study NCT00262067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
Study NCT00262067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consisted of the vehicle for bevacizumab without the antibody.
Study NCT00262067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~1. Docetaxel 75-100 mg/m\^2 IV~2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle
Study NCT00262067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~1. Docetaxel 75-100 mg/m\^2 IV~2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle
Study NCT01735981 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video game exercise using Dance Dance Revolution
Description: use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance
Study NCT01735981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video game exercise using Dance Dance Revolution
Description: use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance
Study NCT01547416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose
Description: Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .~Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg.
Study NCT01547416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no epidural drug administered
Description: Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg.
Study NCT01266213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Goserelin
Description: Fulvestrant s.c. plus Goserelin s.c.
Study NCT01266213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant plus Goserelin
Description: Fulvestrant s.c. plus Goserelin s.c.
Study NCT01609608 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: whole body vibration
Description: to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
Study NCT01609608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
Study NCT02164058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TandemHeart System
Study NCT02164058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Study NCT02164058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Study NCT01735981 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hand-held video game
Description: hand-held video games
Study NCT01735981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand-held video game
Description: hand-held video games
Study NCT01901952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive education and lifestyle support
Description: Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.
Study NCT01901952 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care control group
Description: Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
Study NCT05847023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LUNA
Description: see description above
Study NCT03133208 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draws
Description: Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
Study NCT04311294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANS-6637 Low Dose
Description: ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
Study NCT04311294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANS-6637 High Dose
Description: ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
Study NCT04311294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
Study NCT00459355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Safety Toolkit
Description: Health literacy-verified booklet and home safety items to promote competence to make home safety modifications.
Study NCT04474171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCI&U online health coaching program
Description: Online secure videoconferencing health coaching platform with resource library to promote self-management. Maximum number of sessions is 14 over 6 months and covers health related topics to reduce secondary complications
Study NCT02864576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation_Aerobic Exercise
Description: Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Aerobic Exercise:~12 weeks of systematic aerobic exercise program. Patients will walk with a moderate intensity 10 minutes the first week and will increase gradually up to 30 minutes-walk with a moderate intensity. Patients will also perform 5 minutes of warm-up and stretching.
Study NCT02864576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation_Health Promotion
Description: Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Health Promotion:~12 weeks of health promotion sessions. These sessions will be carried out by a specialized/trained nurse.
Study NCT00766740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy devices
Description: mechanical or manual devices able to remove thrombus from the coronary arteries.
Study NCT00766740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angioplasty
Description: percutaneous coronary angioplasty with use of balloon catheters and bare metal stents or drug eluting stents.
Study NCT02955212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablets for oral administration
Study NCT02955212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets for oral administration
Study NCT02955212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration
Study NCT01519310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic (metronidazole and ciprofloxacin)/probiotic
Description: Antibiotic cocktail/yogurt as follows:~Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks.
Study NCT03223350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.1% Cream
Description: Topical application
Study NCT03223350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo cream
Study NCT04365010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate Ringer's Injection
Description: For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
Study NCT04365010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
Study NCT03288064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corinthian currant
Description: Supplementation of 1.5 g CHO/kg BW in the form of Corinthian currant prior to exercise
Study NCT03288064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose drink
Description: Supplementation of 1.5 g CHO/kg BW in the form of glucose drink prior to exercise
Study NCT03288064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water ingestion
Description: Supplementation of 7ml/kg BW prior to exercise
Study NCT01121250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Discussion Groups
Description: Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
Study NCT01121250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education sessions
Description: Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
Study NCT02365987 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Interesterified blend of palm kernal and plam stearin
Description: 50g fat provided as interesterified palm kernal and palm sterin blend in a single meal